Mitochondrial targeted doxorubicin derivatives delivered by ROS-responsive nanocarriers to breast tumor for overcoming of multidrug resistance
Xin-Cheng Zhong1, Ming-Han Shi2, Hui-Na Liu1
1Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People's Republic of China.
Abstract:
Multidrug resistance (MDR) is a serious challenge in chemotherapy and also a major threat to breast cancer treatment. As an intracellular energy factory, mitochondria provide energy for drug efflux and are deeply involved in multidrug resistance. Mitochondrial targeted delivery of doxorubicin can overcome multidrug resistance by disrupting mitochondrial function. By incorporating a reactive oxygen species (ROS)-responsive hydrophobic group into the backbone structure of hyaluronic acid - a natural ligand for the highly expressed CD44 receptor on tumor surfaces, a novel ROS-responsive and CD44-targeting nano-carriers was constructed. In this study, mitochondria-targeted triphenylphosphine modified-doxorubicin (TPP-DOX) and amphipathic ROS-responsive hyaluronic acid derivatives (HA-PBPE) were synthesized and confirmed by 1H NMR. The nanocarriers TPP-DOX @ HA-PBPE was prepared in a regular shape and particle size of approximately 200 nm. Compared to free DOX, its antitumor activity in vitro and tumor passive targeting in vivo has been enhanced. The ROS-responsive TPP-DOX@HA-PBPE nanocarriers system provide a promising strategy for the reverse of MDR and efficient delivery of doxorubicin derivatives into drug-resistant cancer cells.
Insights
This study developed novel nanocarriers to overcome multidrug resistance in breast cancer. These targeted nanoparticles deliver doxorubicin effectively, enhancing antitumor activity and providing a promising chemotherapy strategy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Multidrug resistance (MDR) significantly challenges chemotherapy efficacy, particularly in breast cancer treatment.
- Mitochondria play a crucial role in MDR by providing energy for drug efflux.
- Targeting mitochondria with drugs like doxorubicin offers a strategy to overcome MDR.
Purpose of the Study:
- To develop novel ROS-responsive and CD44-targeting nanocarriers for enhanced doxorubicin delivery.
- To investigate the potential of these nanocarriers in overcoming MDR in breast cancer.
Main Methods:
- Synthesis of mitochondria-targeted doxorubicin (TPP-DOX) and ROS-responsive hyaluronic acid derivatives (HA-PBPE).
- Characterization of nanocarriers (TPP-DOX@HA-PBPE) with a particle size of approximately 200 nm.
- Evaluation of in vitro antitumor activity and in vivo tumor passive targeting.
Main Results:
- Successfully synthesized and characterized TPP-DOX and HA-PBPE, forming stable TPP-DOX@HA-PBPE nanocarriers.
- Demonstrated enhanced in vitro antitumor activity compared to free doxorubicin.
- Showcased improved tumor passive targeting in vivo.
Conclusions:
- The developed ROS-responsive TPP-DOX@HA-PBPE nanocarrier system shows promise for reversing MDR.
- This strategy facilitates efficient delivery of doxorubicin derivatives into drug-resistant cancer cells.
- Offers a novel approach for overcoming chemotherapy resistance in breast cancer.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...


